We provide you with 20 years of free, institutional-grade data for MTCR stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MTCR. Explore the full financial landscape of MTCR stock.
| Reported Date | CIK | Ticker | Type |
|---|
Metacrine, Inc(NASDAQ:MTCR) 
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases. It is developing MET409 that has completed Phase 1b proof-of-concept clinical trial for the treatment of patients with non-alcoholic ste...
Website: http://www.metacrine.com
Founded: 2014
CEO: Preston S. Klassen
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about MTCR stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.